Publications - IR Sant Pau

Search

01/11/2025 Clinicopathological and molecular features of recurrence in ctDNA-negative resected colorectal cancer

Beltran, JS, Pérez, MARSM, Manrique, ACV, Cullell, BM, Munoz, MN, Mateo, FJP, Riera, P, Fuste, V, Fumagalli, C, Szafranska, J, Catasus, L, Gonzalez, A, Paez, D. Clinicopathological and molecular features of recurrence in ctDNA-negative resected colorectal cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1344. PMID:. IF:65.400(Q1/1D).

01/11/2025 Methotrexate-Induced Gouty Arthritis in Psoriatic Patient

Carmona-Rocha, E, Torné, CD, Alonso, AML, Puig, L. Methotrexate-Induced Gouty Arthritis in Psoriatic Patient. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.02.050. PMID:40615030. IF:(Q/D).

01/11/2025 Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial

Ballesteros, PA, García-Carbonero, I, Gonzalez, EE, Marin, AP, Lorente, D, de Liaño, AG, Ortega, EM, Colomo, LJ, Puente, J, Gonzalez, I, Calvo, OF, Palacios, GA, Mendizabal, I, Navarro, EP, Domínguez, JID, Esteban-Villarrubia, J, Billalabeitia, EG, Oria, GAD. Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3696. PMID:. IF:65.400(Q1/1D).

01/11/2025 Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry

España, MAG, Calle, SG, Flores, EG, Sosa, MM, Tocino, RV, Plazas, JG, Monteagudo, RF, Aguilera, MJS, Herrero, MDRM, Gargia, TG, Zafra, GM, Arévalo, MA, Orozco, EJ, Manrique, ACV, Alfonso, PG, Montes, AF, Ninerola, RQ, de Castro, EM, Verdaguer, H, García, RV. Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1362. PMID:. IF:65.400(Q1/1D).

01/11/2025 Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment

Ahrens, M, Haanen, JBAG, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Rottey, S, Floercken, A, Rodriguez, CS, Rey, JPM, Burkholder, I, Hartmann, A, Bergmann, L. Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3211. PMID:. IF:65.400(Q1/1D).

01/11/2025 Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Sanborn, RE, Zhou, CC, Tang, KJ, Cho, BC, Cheng, S, Popat, S, Ono, A, Lu, S, Majem, M, Aguilar, A, Campelo, MDG, Hayashi, H, Lee, KY, Lee, SH, Delmonte, A, Alatorre-Alexander, J, Richardson, G, Santos, V, Dooms, C, Sabari, JK, Shu, CA, Girard, N, Mansfield, AS, Park, K, Xia, YC, Bhattacharya, A, Buyukkaramikli, N, Perualila, N, Diels, J, Acharya, S, Chandler, C, Proskorovsky, I, Dearden, L, Wortman-Vayn, H, Mahadevia, PJ, Knoblauch, RE, Agrawal, T, Baig, M, Felip, E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Targeted Oncology. 2025; 20(6)DOI:10.1007/s11523-025-01182-0. PMID:41184595. IF:4.000(Q2/3D).

01/11/2025 Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study

Muñoz-Couselo, E, Berciano-Guerrero, MA, Crespo, G, Castaño, AG, Manzano, JL, Miguel, PAD, Rosa, CA, Cerezuela-Fuentes, P, Puértolas, T, Sanz, LG, Medina, J, Cunquero-Tomás, A, Majem, M, Fernández, LA, Espinosa, E, Bellido, L, Soria, A, Bujosa, A, Algarra, SM, Marquez-Rodas, I. Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2263. PMID:. IF:65.400(Q1/1D).

01/11/2025 Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer

Bergmann, L, Albiges, L, Ahrens, M, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Floercken, A, Rodriguez, CS, Rey, JPM, Gruenwald, V, Burkholder, I, Hartmann, A, Haanen, JBAG. Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3216. PMID:. IF:65.400(Q1/1D).

01/11/2025 International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study

Chen, TWW, Giani, C, Ljevar, S, Reinhorn, D, Denu, R, Bhadri, VA, Jaeger, R, Ibrahim, T, D'Ambrosio, L, Bae, S, Han, I, Garcia, AS, Abreu, MH, Ribeiro, MFSA, Mariuk-Jarema, A, Yang, V, Sbaraglia, M, Antonescu, C, Baldi, GG, Stacchiotti, S. International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3306. PMID:. IF:65.400(Q1/1D).

01/11/2025 Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study

Muñiz, NH, Strauss, S, Redondo, A, Palmerini, E, Gaffaro, GJM, Chamberlain, FE, Martinez, V, Ibrahim, T, Trufero, JM, Morales, CMV, Billalabeitia, EG, Lleida, RT, Jiménez, CL, Mukherjee, U, Wan, S, Ramos, R, Garcia, AMG, Moura, DD, Martin-Broto, J. Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3296. PMID:. IF:65.400(Q1/1D).

01/11/2025 Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients

Lopez, JS, Besora, CP, Malaret, M, Joaquín, AB, Recio, SM, Momblan, AM, Dalmau, GM, Majem, M. Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3451. PMID:. IF:65.400(Q1/1D).

01/11/2025 Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma

Blay, JY, Lleida, RT, Martin-Broto, J, Caetano, C, De Haan, JJ, Debruyne, C, Desar, I, Duffaud, F, Gelderblom, H, Gennigens, C, Italiano, A, Colomo, LJ, Lapeire, L, Mazzeo, F, Philip, J, Striefler, JK, Svobodova, M, Tala, I, Morales, CMV, Stacchiotti, S. Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3359. PMID:. IF:65.400(Q1/1D).

01/11/2025 Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial

Molasiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, LS, Bonizzoni, E, Vazquez, EB, Buchler, T, Cheng, Y, Christoph, DCC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanova, M, Aapro, MS. Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3413. PMID:. IF:65.400(Q1/1D).

01/11/2025 Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study

Sepulveda, ZV, Tous, S, Quiros, B, Pena, GP, Castro, JB, Serrahima, MP, Galiana, IL, Marí, A, Brunet, A, Bermejo, JO, Cirauqui, BC, Diez, AF, Leon, X, Sumarroca, A, Giner, M, Clavero, O, Goma, M, Pavon, MA, Alemany, L, Bernal, MO. Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2028. PMID:. IF:65.400(Q1/1D).

01/11/2025 Pharmacogenetics in advanced Parkinson's disease

Kulisevsky, J, García-Ruíz, P, Outeiro, TF, Gurevich, T, Klivènyi, P, Van Laar, T, Milanov, I, Pirker, W, Popescu, BO, Toft, M, Szász, JA. Pharmacogenetics in advanced Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION. 2025; 132(11)DOI:10.1007/s00702-025-03057-0. PMID:41222708. IF:4.000(Q1/2D).

01/11/2025 Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients

Garcia-Forn, M, Castany-Pladevall, C, Creus-Muncunill, J, Golbano, A, Escaramís, G, Pérez-Pérez, J, Balantzategi, U, Hernan-Godoy, M, Brito, V, Kulisevsky, J, Martí, E, Pérez-Navarro, E. Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients. Neurotherapeutics. 2025; 22(6)DOI:10.1016/j.neurot.2025.e00716. PMID:40774881. IF:6.900(Q1/1D).

01/11/2025 BioFace3D: An end-to-end open-source software for automated extraction of potential 3D facial biomarkers from MRI scans

Heredia-Lidón, A, Echeverry-Quiceno, LM, González, A, Hostalet, N, Pomarol-Clotet, E, Fortea, J, Fatjó-Vilas, M, Martínez-Abadías, N, Sevillano, X. BioFace3D: An end-to-end open-source software for automated extraction of potential 3D facial biomarkers from MRI scans. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE. 2025; 271DOI:10.1016/j.cmpb.2025.109010. PMID:40818363. IF:4.800(Q1/1D).

01/11/2025 Associations of lifestyle factors with amyloid pathology in persons without dementia

Oomens, JE, Vos, SJB, Maserejian, NN, Boada, M, Didic, M, Engelborghs, S, Fladby, T, van der Flier, WM, Frisoni, GB, Fröhlich, L, Gill, KD, Grimmer, T, Hort, J, Itoh, Y, Iwatsubo, T, Klimkowicz-Mrowiec, A, Landau, SM, Lee, DY, Lleó, A, Martinez-Lage, P, de Mendonça, A, Meyer, PT, Parchi, P, Pardini, M, Parnetti, L, Popp, J, Rami, L, Reiman, EM, Rinne, JO, Rodrigue, KM, Sánchez-Juan, P, Santana, I, Scarmeas, N, Scheltens, P, Skoog, I, Sperling, RA, Stern, Y, Villeneuve, S, Waldemar, G, Wiltfang, J, Zetterberg, H, Alcolea, D, Allegri, RF, Altomare, D, Bateman, RJ, Baiardi, S, Baldeiras, I, Blennow, K, den Braber, A, van Buchem, MA, Byun, MS, Cerman, J, Chen, KW, Chipi, E, Day, GS, Drzezga, A, Ekblad, LL, Förster, S, Fortea, J, Freund-Levi, Y, Frings, L, Guedj, E, Habeck, CG, Handels, R, Hausner, L, Hellwig, S, Jiménez-Bonilla, JF, Juaristi, AI, Kandimalla, R, Kern, S, Kirsebom, BESB, Kornhuber, J, Legdeur, N, Levin, J, Maier, W, Marquié, M, Minatani, S, Morbelli, SD, Mroczko, B, Ntanasi, E, de Oliveira, CR, Orellana, A, Peters, O, Prabhakar, S, Ramakers, IH, Rodríguez-Rodriguez, E, Ruiz, A, Rüther, E, Sakhardande, J, Selnes, P, Silva, D, Soininen, H, Spiru, L, Takeda, A, Teunissen, CE, Tijms, BM, Vermunt, L, Wallin, ÅK, Wiels, W, Yannakoulia, M, Yi, D, Zettergren, A, Ossenkoppele, R, Verhey, FRJ, Visser, PJ, Jansen, WJ. Associations of lifestyle factors with amyloid pathology in persons without dementia. JOURNAL OF ALZHEIMERS DISEASE. 2025; 108(3)DOI:10.1177/13872877251379083. PMID:41234025. IF:3.100(Q2/5D).

01/11/2025 Severe Neutropenia in Infants With Congenital Cytomegalovirus on Antiviral Therapy

Papaevangelou, V, Pedrero-Tomé, R, Syridou, G, Baquero-Artigao, F, Rodríguez-Molino, P, del Rosal, T, Noguera-Julián, A, Ríos-Barnés, M, Fortuny, C, Villaverde, S, Frick, MA, Vallejo, BA, Soler-Palacín, P, Saavedra, J, Karagiannidou, S, Rincón, E, Busselo, IS, Zuriarrain, OM, Calderón, EM, Tagarro, A, Malumbres, M, Colino, E, Llanos, EG, Ruiz, AM, Mateos, MS, Espuny, XB, Alonso-Ojembarrena, A, Ferreras-Antolin, L, Pérez, IC, Posse, AF, Lyall, H, Blázquez-Gamero, D. Severe Neutropenia in Infants With Congenital Cytomegalovirus on Antiviral Therapy. PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2025; 44(11)DOI:10.1097/INF.0000000000004905. PMID:40674644. IF:2.200(Q2/3D).

01/11/2025 Longitudinal Characterization of Patient-Ventilator Asynchronies in Acute Hypoxemic Respiratory Failure

de Haro, C, Xifra-Porxas, A, Batlle, M, Sarlabous, L, Santos-Pulpón, V, Mora, V, Suñol, F, Gomà, G, Estela, J, Subirà, C, López-Aguilar, J, Fernández-Gonzalo, S, Godoy-González, M, Fernández, R, Magrans, R, Telias, I, Roca, O, Brochard, L, Blanch, L. Longitudinal Characterization of Patient-Ventilator Asynchronies in Acute Hypoxemic Respiratory Failure. Respiratory Care. 2025; 70(11)DOI:10.1089/respcare.12673. PMID:40441677. IF:2.100(Q3/6D).

01/11/2025 Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?

Fernández, CPH, Borrego, L, Arnau, AMG, Sánchez, TS, Carrillo, JMC, Ninet, VZ, Baldrich, ES, Miquel, FJM, Salvador, JFS, Guijarro, SC, Gilo, AS, García, PM, Triviño, FN, Romero, FT, Serna, MR, Ninot, GM, González, IR, de la Fuente, EG, Nieto, MAP, Guillén, PSP, Pérez, JS, Rodríguez, JJP, Ortega, MEG, Pérez, RG, Doval, IG, Descalzo, MAG. Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.10.063. PMID:40024601. IF:(Q/D).

01/11/2025 Oncologic Outcomes of Endoscopic Management of Upper Tract Urothelial Carcinoma: A Systematic Review and Pooled Analysis from the EAU-YAU Urothelial Working Group

Gallioli, A, Uleri, A, Verri, P, Tedde, A, Mertens, LS, Moschini, M, Del Giudice, F, Soria, F, Laukhtina, E, Subiela, JD, Krajewski, W, D'Andrea, D, Mari, A, Marcq, G, Mori, K, Teoh, J, Afferi, L, Albisinni, S, Sanguedolce, F, Palou, J, Breda, A, Pradere, B. Oncologic Outcomes of Endoscopic Management of Upper Tract Urothelial Carcinoma: A Systematic Review and Pooled Analysis from the EAU-YAU Urothelial Working Group. European Urology Focus. 2025; 11(3)DOI:10.1016/j.euf.2025.01.009. PMID:39894734. IF:5.600(Q1/1D).

01/11/2025 Oncological Outcomes in Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives

Longonia, M, Scilipoti, P, Soria, F, Pradere, B, Krajewski, W, D'Andreaf, D, Mari, A, Del Giudiceh, F, Pichleri, R, Subielaj, JD, Afferik, L, Albisinnil, S, Gallioli, A, Mertens, LS, Laukhtinaf, E, Morio, K, Radziszewskip, P, Slusarczykp, A, Shariat, SF, Necchi, A, Xylinas, E, Gontero, P, Roupret, M, Montorsi, F, Briganti, A, Moschini, M. Oncological Outcomes in Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives. European Urology Oncology. 2025; 8(5)DOI:10.1016/j.euo.2025.03.007. PMID:40204534. IF:9.300(Q1/1D).

01/11/2025 Challenges in Follow-up After Kidney-sparing Surgery for Upper Tract Urot helial Carcinoma: Insights from a Delphi Consensus

Figaroa, O, Schuil, H, Kamphuis, G, van den Brink, L, Hendriks, N, Henderickx, M, Bins, A, van Moorselaar, J, Ajayi, L, Bus, M, Cavadas, V, Cracco, CM, Andrea, DD, Dasgupta, R, De Coninck, V, Durutovic, O, Ebbensgaard, I, Ferretti, S, Gallioli, A, Keller, EX, Keeley, FX Jr, Osther, PJS, Popiolek, M, Pradere, B, Proietti, S, Saltirov, I, Somani, B, Tailly, T, Thomas, K, Turney, B, Ulvik, O, van Haute, C, van der Heij, B, Vasquez, JL, Brehmer, M, Baard, J. Challenges in Follow-up After Kidney-sparing Surgery for Upper Tract Urot helial Carcinoma: Insights from a Delphi Consensus. European Urology Oncology. 2025; 8(5)DOI:10.1016/j.euo.2025.07.003. PMID:40816958. IF:9.300(Q1/1D).

01/11/2025 Understanding ICU Outcomes: Lessons From National ICU Registries

Moralez, GM, Ranzani, OT, Quintairos, A, Salluh, JIF. Understanding ICU Outcomes: Lessons From National ICU Registries. CRITICAL CARE MEDICINE. 2025; 53(11)DOI:10.1097/CCM.0000000000006853. PMID:40920041. IF:6.000(Q1/1D).

01/11/2025 Prevalence and Impact of Violence Against Healthcare Workers in Brazilian Emergency Departments: A National Survey

de Carvalho, JMD, McGuire, SS, Oliveira, LLR, Bellolio, F, Ranzani, OT, Besen, BAMP, Guimaraes, HP, Lunardi, MC, Mullan, AF, Hajjar, LA, Maia, IWA. Prevalence and Impact of Violence Against Healthcare Workers in Brazilian Emergency Departments: A National Survey. Western Journal of Emergency Medicine. 2025; 26(6)DOI:10.5811/westjem.45138. PMID:41380058. IF:2.000(Q2/4D).

01/11/2025 Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Brandao, M, Prisciandaro, E, Xenophontos, E, Mariolo, A, Sadeghi, AH, Filippi, AR, Levy, A, Bandura, A, Caramella, C, Dickhoff, C, de Margerie-Mellon, C, Faivre-Finn, C, Portik, D, Sanchez-Lorente, D, De Ruysscher, D, Smit, E, Gobbini, E, Fadel, E, Ruffini, E, Olmetto, E, Cortiula, F, Bahce, I, Houda, I, Opitz, I, Naidoo, J, Edwards, J, Remon, J, Benitez, JC, Trujillo, JC, Derks, J, Amrane, K, Hartemink, KJ, Stathopoulos, K, Hendriks, LEL, Iglesias, M, Occhipinti, M, Guckenberger, M, Levra, NG, Girard, N, Reguart, N, Mercier, O, Bironzo, P, Hofman, P, Petersen, RH, De Angelis, R, Abgral, R, Terrisse, S, Popat, S, Pierret, T, Blum, TG, Ricardi, U, Dionisi, V, Berghmans, T, Dingemans, AMC. Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108798. PMID:41108881. IF:4.400(Q1/2D).

01/11/2025 Transcatheter Tricuspid Valve Annuloplasty with the Cardioband System: A Step-by-Step Guide

Novembre, ML, Asmarats, L, Li, CHP, Santalo-Corcoy, M, Millán, X, Arzamendi, D. Transcatheter Tricuspid Valve Annuloplasty with the Cardioband System: A Step-by-Step Guide. Journal of Clinical Medicine. 2025; 14(21)DOI:10.3390/jcm14217772. PMID:41227168. IF:2.900(Q1/2D).

01/11/2025 Pacemaker Risk Stratification in Patients With Pre-existing Right Bundle Branch Block Undergoing Transcatheter Aortic Valve Replacement

Travieso, A, Nuche, J, Tirado-Conte, G, Cheema, AN, Tamargo, M, Muntané-Carol, G, Asmarats, L, Becerra-Muñoz, VM, Del Valle, R, Rivero, F, Pena, JCS, Cordon, CF, Martinez-Selles, M, Muñoz-Garcia, AJ, Lopez, D, Alonso-Briales, JH, Gonzalo, N, Alfonso, F, Arzamendi, D, Gomez-Hospital, JA, Rodés-Cabau, J, Nombela-Franco, L. Pacemaker Risk Stratification in Patients With Pre-existing Right Bundle Branch Block Undergoing Transcatheter Aortic Valve Replacement. CANADIAN JOURNAL OF CARDIOLOGY. 2025; 41(11)DOI:10.1016/j.cjca.2025.06.076. PMID:40623499. IF:5.300(Q1/2D).

01/11/2025 Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study

Puente, A, Turón, F, Martínez, J, Fortea, JI, Guerra, MH, Alvarado, E, Pons, M, Magaz, M, Llop, E, Alvarez-Navascués, C, Navarrete, AA, Berenguer, M, Masnou, H, Bañares, R, Casado, M, Ampuero, J, Rios, J, Saavedra, C, Blasi, A, Lisman, T, Figuero, CR, Huelin, P, Tellez, L, Arráez, DM, Rodriguez, M, Aguilera, V, Loste, MTA, Baiges, A, Hernandez-Gea, V, Perelló, C, Calleja, JL, Genescà, J, Villanueva, C, Gonzalez-Alayón, C, Albillos, A, Crespo, J, Garcia-Pagán, JC. Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study. JOURNAL OF HEPATOLOGY. 2025; 83(5)DOI:10.1016/j.jhep.2025.06.035. PMID:40691992. IF:33.000(Q1/1D).

01/11/2025 Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP

Martinez-Brocca, MA, Bellido, V, Cardona-Hernandez, R, Castaño, L, Conget, I, Fernández, A, Gila, ALG, Leiva-Gea, I, Mauricio, D. Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP. Endocrinologia Diabetes y Nutricion. 2025; 72(9)DOI:10.1016/j.endinu.2025.501639. PMID:41111054. IF:1.800(Q3/8D).

01/11/2025 Oxytocin in hypopituitarism: What do we know?

Aulinas, A, Lawson, EA. Oxytocin in hypopituitarism: What do we know?. Endocrinologia Diabetes y Nutricion. 2025; 72(9)DOI:. PMID:41173566. IF:1.800(Q3/8D).

01/11/2025 Unraveling the gut-fat-inflammation connection in Crohn's disease: A path to new therapeutic targets?

Giordano, A, Bastón-Rey, I, Madero, L, Brunet-Mas, E, Calafat, M. Unraveling the gut-fat-inflammation connection in Crohn's disease: A path to new therapeutic targets?. Gastroenterologia y Hepatologia. 2025; 48(9)DOI:10.1016/j.gastrohep.2025.502466. PMID:40378950. IF:1.900(Q3/7D).

01/11/2025 Colonoscopy in symptomatic patients: Validation of AEG-SEED prioritization criteria and added value of FIT. The endoprior study

Rivero-Sánchez, L, Castillo-Iturra, J, Garcia-Rodriguez, A, Zafra, BG, Redondo, PD, Rodriguez, HN, Ponce, M, San Juan, M, Barrera, PB, Seoane, A, Carrasco, MA, Zaffalon, D, Guarner, C, Murzi, M, Jover, R, Medina-Prado, L, Rubio, KA, Matias, DJ, Suárez, BG, Córdova, H, Fernández-Simón, A, Araujo, I, Ginés, A, Pellisé, M, Balaguer, F, Fernández-Esparrach, G. Colonoscopy in symptomatic patients: Validation of AEG-SEED prioritization criteria and added value of FIT. The endoprior study. Gastroenterologia y Hepatologia. 2025; 48(9)DOI:10.1016/j.gastrohep.2025.502471. PMID:40409590. IF:1.900(Q3/7D).

01/11/2025 Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis (vol 83, pg 70, 2025)

Fortea, JI, Alvarado-Tapias, E, Simbrunner, B, Ezcurra, I, Hernández-Gea, V, Aracil, C, Llop, E, Puente, A, Roig, C, Reiberger, T, Garcia-Pagan, JC, Calleja, JL, Ferrero-Gregori, A, Mandorfer, M, Villanueva, C, Crespo, J. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis (vol 83, pg 70, 2025). JOURNAL OF HEPATOLOGY. 2025; 83(5)DOI:10.1016/j.jhep.2025.08.004. PMID:40914642. IF:33.000(Q1/1D).

01/11/2025 Mapping MSU crystal deposition within MTP joints in tophaceous gout: a dual-energy CT study

De Silva, C, Díaz-Torné, C, Gamble, G, Horne, A, Doyle, A, Stamp, LK, Dalbeth, N. Mapping MSU crystal deposition within MTP joints in tophaceous gout: a dual-energy CT study. RHEUMATOLOGY. 2025; 64(11)DOI:10.1093/rheumatology/keaf347. PMID:40581776. IF:4.400(Q1/1D).

01/11/2025 Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain

Camps-Vilaró, A, Teira, R, Subirana, I, Dégano, IR, Domingo, P, Curran, A, Montero-Alonso, M, Romero, A, Marrugat, J, Galindo, MJ. Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025; 160DOI:10.1016/j.ijid.2025.108061. PMID:40953693. IF:4.300(Q1/2D).

01/11/2025 Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer

Simoes, AR, González, SC, Lopez-Doldan, MD, Duran, G, Fernández-Montes, A, Fernandez, MP, Fernandez, MS, Mata, JG, Paez, D, Riera, P, Guino, E, Lopez-Fernandez, L, de Santiago, BG, Aspiroz, EL, Rojas, A, Castells, A, Castellvi-Bel, S, Ponte, CR, Vymetalkova, V, Carracedo, A, Fernandez-Rozadilla, C. Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer. BRITISH JOURNAL OF PHARMACOLOGY. 2025; 182(21)DOI:10.1111/bph.70051. PMID:40624839. IF:7.700(Q1/1D).

01/11/2025 Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108763. PMID:41033130. IF:4.400(Q1/2D).

01/11/2025 Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial

Soler, G, Grávalos, C, Rivera, F, Safont, MJ, Virgili, AC, Valladares-Ayerbes, M, Ferreiro-Monteagudo, R, Ortiz-Morales, MJ, Polo-Marques, E, Kornusova-Bersheva, I, Soustre, E, Yao, WY, Élez, E. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03907-z. PMID:40338282. IF:2.500(Q3/6D).

01/11/2025 Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108799. PMID:41108882. IF:4.400(Q1/2D).

01/11/2025 Self-disintegrating protein-leaking microparticles for topical protein delivery

Volta-Durán, E, Sánchez, JM, Favaro, MTP, Martinez-Cuentra, G, Contreras, E, di Somma, A, López-Laguna, H, Unzueta, U, Casanova, I, Mangues, R, Villaverde, A, Vázquez, E. Self-disintegrating protein-leaking microparticles for topical protein delivery. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2025; 329DOI:10.1016/j.ijbiomac.2025.147730. PMID:40967544. IF:8.500(Q1/1D).

01/11/2025 Nanotoxin induces in situ pyroptosis to sensitize aPD1 to ablate metastases in microsattellite stable colorectal cancer

Carrasco-Díaz, LM, Otero-Mateo, M, Alamo, P, Gallardo, A, Virgili, AC, Páez, D, Voltà-Durán, E, Villaverde, A, Vázquez, E, Unzueta, U, Casanova, I, Alba-Castellon, L, Mangues, R. Nanotoxin induces in situ pyroptosis to sensitize aPD1 to ablate metastases in microsattellite stable colorectal cancer. PHARMACOLOGICAL RESEARCH. 2025; 221DOI:10.1016/j.phrs.2025.107982. PMID:41083088. IF:10.500(Q1/1D).

01/11/2025 Prognostic value of pretreatment peripheral blood biomarkers in patients with head and neck squamous cell carcinoma treated with chemo/bioradiotherapy

Sansa, A, Vásquez, R, Valero, C, Vázquez, C, Holgado, A, Gayà, J, Rubio, D, León, X. Prognostic value of pretreatment peripheral blood biomarkers in patients with head and neck squamous cell carcinoma treated with chemo/bioradiotherapy. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03897-y. PMID:40323571. IF:2.500(Q3/6D).

01/11/2025 Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma

Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).

01/11/2025 Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia

Grasa, E, Forment, A, Alonso-Solís, A, Ramalho, L, Roldán, A, Pousa, E, Aussó, S, Berdun, J, Tesoro, AG, Escudero, J, Corripio, I. Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia. ACTAS ESPANOLAS DE PSIQUIATRIA. 2025; 53(6)DOI:10.62641/aep.v53i6.1959. PMID:41437755. IF:1.600(Q3/7D).

01/11/2025 Clinical practice guide for nurses that optimizes nurse's comprehensive care of patients undergoing immunotherapy

Serra-Lopez, J, Miranda, A, Soria, A, Lopez, N, Castañon, E, Majem, M. Clinical practice guide for nurses that optimizes nurse's comprehensive care of patients undergoing immunotherapy. Enfermeria Clinica. 2025; 35(6)DOI:10.1016/j.enfcle.2025.502193. PMID:40204238. IF:(Q/D).

01/11/2025 Use of nebulized bronchodilators in acute heart failure: impact on outcomes

Miró, O, Ivars, N, Espinosa, B, Jacob, J, Alquézar-Arbé, A, Gil, V, Bellido, A, Serrano, L, Herrero-Puente, P, Fortuny, MJ, Mir, M, Soy, E, Esquivias, MA, Tost, J, Travería, L, Domingo, E, Noceda, J, López-Diez, MP, Aguirre, A, Alonso, H, Romero, M, López-Grima, ML, López, ML, Mueller, C, Peacock, WF, Puente, PH. Use of nebulized bronchodilators in acute heart failure: impact on outcomes. Internal and Emergency Medicine. 2025; 20(8)DOI:10.1007/s11739-025-04123-x. PMID:41162690. IF:3.800(Q1/2D).

01/11/2025 The MULTISENT Study: A Multicenter Study on the Detection Rate of Sentinel Lymph Node Mapping in Endometrial Cancer Across Spain

Gómez-Hidalgo, NR, Cabrera, S, Bebia, V, García-Pineda, V, Padilla-Iserte, P, Fabregas, FF, Fuste, P, Alonso, P, Rodriguez, TG, Fernandez-Gonzalez, S, Chacon, E, Alvarez, JAP, Oliver, R, Gil-Moreno, A. The MULTISENT Study: A Multicenter Study on the Detection Rate of Sentinel Lymph Node Mapping in Endometrial Cancer Across Spain. ANNALS OF SURGICAL ONCOLOGY. 2025; 32(12)DOI:10.1245/s10434-025-17836-2. PMID:40702200. IF:3.500(Q1/2D).

01/11/2025 Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: consensus of the scientific societies SED, SEEN and SEEP.

Martinez-Brocca, Maria Asuncion, Bellido, Virginia, Cardona-Hernandez, Roque, Castaño, Luis, Conget, Ignacio, Fernandez, Alberto, Gomez Gila, Ana Lucia, Leiva-Gea, Isabel, Mauricio, Didac. Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: consensus of the scientific societies SED, SEEN and SEEP.. Anales De Pediatria. 2025; 103(5)DOI:10.1016/j.anpede.2025.503944. PMID:. IF:(Q/D).

01/11/2025 Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU

Llao, J, Mañosa, M, Martín-Arranz, E, Zabana, Y, Navarro-Llavat, M, Téller, M, Garcia-Planella, E, Busquets, D, Monfort, D, Pineda, JR, Gutiérrez, A, Villoria, A, Menchén, L, Bastida, G, García-Alonso, FJ, Rivero, M, Chaparro, M, de Francisco, R, Merino, O, Rodríguez-Lago, I, Acosta, MBD, Rodríguez-Fortúnez, P, Rodríguez-Jiménez, C, Calafat, M, Domènech, E. Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU. Journal of Crohns & Colitis. 2025; 19(11)DOI:10.1093/ecco-jcc/jjaf182. PMID:41258993. IF:8.700(Q1/1D).

01/11/2025 Consensus on acromegaly therapeutic outcomes: an update

Melmed, S, di Filippo, L, Fleseriu, M, Mercado, M, Karavitaki, N, Gurnell, M, Salvatori, R, Tsagarakis, S, Losa, M, Maffei, P, Pereira, AM, Geer, EB, Katznelson, L, van der Lely, AJ, Bollerslev, J, Esposito, D, Webb, SM, Zatelli, MC, Valassi, E, Neggers, S, Chanson, P, Ho, KKY, Ioachimescu, AG, Biller, BMK, Samson, SL, Kaiser, UB, Schilbach, K, Luque, RM, Casanueva, FF, Shimon, I, Boguszewski, CL, Biermasz, N, Colao, A, Pirchio, R, Lamberts, SWJ, Kadioglu, P, Buchfelder, M, Frara, S, Chiloiro, S, Petersenn, S, Gadelha, MR, Puig-Domingo, M, Luger, A, Brue, T, Beckers, A, Ferone, D, Clemmons, DR, Greenman, Y, Marazuela, M, Mortini, P, Strasburger, CJ, Giustina, A. Consensus on acromegaly therapeutic outcomes: an update. Nature Reviews Endocrinology. 2025; 21(11)DOI:10.1038/s41574-025-01148-2. PMID:40804505. IF:40.000(Q1/1D).

01/11/2025 A Metagenomics Approach to Frailty in Patients With Cirrhosis Undergoing a Multifactorial Intervention

Vega-Abellaneda, S, Román, E, Soler, Z, Ortiz, MA, Rossi, G, Biagini, L, Sánchez, E, Pons-Tarin, M, Laghi, L, Mengucci, C, Kaur, N, Poca, M, Cuyàs, B, Serrano-Gomez, G, Alvarado, E, Manichanh, C, Soriano, G. A Metagenomics Approach to Frailty in Patients With Cirrhosis Undergoing a Multifactorial Intervention. LIVER INTERNATIONAL. 2025; 45(12)DOI:10.1111/liv.70418. PMID:41174950. IF:5.200(Q1/2D).

01/11/2025 First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup))

Portu, M, Martinez-Recio, S, Barba, A, Gonzalez, A, López, L, Catasús, L, Majem, M. First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)). Clinical Lung Cancer. 2025; 26(7)DOI:10.1016/j.clic.2025.07.013. PMID:40774920. IF:3.300(Q2/4D).

01/11/2025 Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024

Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).

01/11/2025 Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021

Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).

01/11/2025 CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas

Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).

01/11/2025 Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus

Casasayas, M, Holgado, A, León, X, Kolanczak, K, Pérez-Sempere, M, Quer, M, Gras-Cabrerizo, JR. Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus. JOURNAL OF LARYNGOLOGY AND OTOLOGY. 2025; 139(11)DOI:10.1017/S0022215125102958. PMID:40734309. IF:0.800(Q3/8D).

01/11/2025 Detection and treatment of early gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Garcia-Patterson, A, Balsells, M, Solà, I, Corcoy, R. Detection and treatment of early gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025; 233(5)DOI:10.1016/j.ajog.2025.04.059. PMID:40320104. IF:8.400(Q1/1D).

01/11/2025 Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review

Asenjo-Lobos, C, Arancibia, M, Garcia-Ribera, C, Cortés-Jofré, M, Huang, TM, Li, T, Madrid, E, Leucht, S. Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review. PSYCHIATRY RESEARCH. 2025; 353DOI:10.1016/j.psychres.2025.116764. PMID:41101242. IF:3.900(Q1/2D).